Advertisement
Screener

GILEAD SCIENCES, INC. (GILD) Proceeds from Issuance of Senior Long-term Debt

1.8 / 5 stars · 42/120 Roast Me

GILEAD SCIENCES, INC. Proceeds from Issuance of Senior Long-term Debt

GILEAD SCIENCES, INC. (GILD) reported Proceeds from Issuance of Senior Long-term Debt of $0 for the 9-month period ending 2012-09-30, per its 10-Q filed 2012-11-06.

Discontinued › Cash Flow › Financing Activities

us-gaap:ProceedsFromIssuanceOfSeniorLongTermDebt · last filed 2012-11-06

  • GILEAD SCIENCES, INC. proceeds from issuance of senior long-term debt for the quarter ending 2012-09-30 was $0.00.
  • GILEAD SCIENCES, INC. proceeds from issuance of senior long-term debt for the quarter ending 2012-06-30 was $0.00.
  • GILEAD SCIENCES, INC. proceeds from issuance of senior long-term debt for the quarter ending 2012-03-31 was $0.00, a 100.00% decline year-over-year.
  • GILEAD SCIENCES, INC. proceeds from issuance of senior long-term debt for the quarter ending 2011-12-31 was $3.67B.
  • GILEAD SCIENCES, INC. proceeds from issuance of senior long-term debt for fiscal 2011 was $4.66B.
  • GILEAD SCIENCES, INC. proceeds from issuance of senior long-term debt for fiscal 2010 was $0.00.
  • GILEAD SCIENCES, INC. proceeds from issuance of senior long-term debt for fiscal 2009 was $0.00.
Period endProceeds from Issuance of Senior Long-term Debt 3 monthProceeds from Issuance of Senior Long-term Debt 6 monthProceeds from Issuance of Senior Long-term Debt 9 monthProceeds from Issuance of Senior Long-term Debt 12 month
2012-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06
$0.00
derived: sum of 2 quarters · filed 2012-11-06
$0.00
10-Q · filed 2012-11-06
$3.67B
derived: sum of 4 quarters · filed 2012-11-06
2012-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01
$0.00
10-Q · filed 2012-08-01
$3.67B
derived: sum of 3 quarters · filed 2012-08-01
$3.67B
derived: sum of 4 quarters · filed 2012-11-06
2012-03-31$0.00
10-Q · filed 2012-05-04
$3.67B
derived: sum of 2 quarters · filed 2012-05-04
$3.67B
derived: sum of 3 quarters · filed 2012-11-06
$3.67B
derived: sum of 4 quarters · filed 2012-11-06
2011-12-31$3.67B
derived: 10-K 12 month − 10-Q 9 month · filed 2012-02-23
$3.67B
derived: sum of 2 quarters · filed 2012-11-06
$3.67B
derived: sum of 3 quarters · filed 2012-11-06
$4.66B
10-K · filed 2012-02-23
2011-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2012-11-06
$0.00
derived: sum of 2 quarters · filed 2012-11-06
$987.37M
10-Q · filed 2012-11-06
2011-06-30$0.00
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-01
$987.37M
10-Q · filed 2012-08-01
2011-03-31$987.37M
10-Q · filed 2012-05-04
2010-12-31$0.00
10-K · filed 2012-02-23
2009-12-31$0.00
10-K · filed 2012-02-23

Similar stocks

Stock NameCountryMarket CapPE Ratio
AMGEN INC (AMGN)United States$219.567B22.39
Moderna, Inc. (MRNA)United States$77.819B-8.86
Revolution Medicines, Inc. (RVMD)United States$42.805B-22.69
BIOGEN INC. (BIIB)United States$33.427B19.60
EXELIXIS, INC. (EXEL)United States$14.358B16.15
NEUROCRINE BIOSCIENCES INC (NBIX)United States$14.131B24.25
HALOZYME THERAPEUTICS, INC. (HALO)United States$13.083B21.59
Twist Bioscience Corp (TWST)United States$11.540B-47.21
BIO-TECHNE Corp (TECH)United States$11.379B74.68
REPLIGEN CORP (RGEN)United States$10.755B185.31